ONCY

MKT CAP:$102M

Oncolytics Biotech Inc.

Market Cap

$102M

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Healthcare·Biotechnology·🇨🇦·NASDAQ

Stock Price

$1.09+$0.11 (+10.81%)

Apr 23, 2026

Company Details

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherap...

CEO

Jared Kelly

IPO Date

Oct 5, 2001

Website

www.oncolyticsbiotech.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$21M

EPS (Diluted)

-$0.22

Free Cash Flow

-$15M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 30, 2026

$0EPS -$0.30

Q4 2025

Mar 30, 2026

$0EPS -$0.01

Q3 2025

Nov 12, 2025

$0EPS -$0.10

Q2 2025

Aug 8, 2025

$0EPS -$0.05

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 19	$0	$0	-$4M
Q2 19	$0	$0	-$4M
Q3 19	$0	$0	-$3M
Q4 19	$0	$0	-$5M
Q1 20	$0	$0	-$4M
Q2 20	$0	$0	-$4M
Q3 20	$0	$0	-$5M
Q4 20	$0	$0	-$6M
Q4 23	$0	-$78.2K	-$6M
Q1 24	$0	-$89.9K	-$6M
Q3 24	$0	$0	-$7M
Q4 24	$0	$0	-$6M
Q1 25	$0	$0	-$5M
Q2 25	$0	$0	-$4M
Q3 25	$0	$0	-$10M
Q4 25	$0	$0	-$2M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 19	-$2M	-$2M
Q2 19	-$3M	-$3M
Q3 19	-$3M	-$3M
Q4 19	-$5M	-$5M
Q1 20	-$3M	-$3M
Q2 20	-$5M	-$5M
Q3 20	-$4M	-$4M
Q4 20	-$4M	-$4M
Q4 23	-$4M	-$4M
Q1 24	-$5M	-$5M
Q3 24	-$4M	-$4M
Q4 24	-$6M	-$6M
Q1 25	-$5M	-$5M
Q2 25	-$4M	-$4M
Q3 25	-$5M	-$5M
Q4 25	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q1 19	$2.0K
Q2 19	$5.0K
Q3 19	$0
Q4 19	$910
Q1 20	$7.8K
Q2 20	$2.2K
Q3 20	$11.4K
Q4 20	$0
Q4 23	$2.2K
Q1 24	$33.6K
Q3 24	$23.4K
Q4 24	$4.4K
Q1 25	$0
Q2 25	$0
Q3 25	$5.1K
Q4 25	$7.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 19	—	+6.2%
Q2 19	—	+44.1%
Q3 19	—	+1.6%
Q4 19	—	+42.2%
Q1 20	—	+10.7%
Q2 20	—	+4.5%
Q3 20	—	+83.0%
Q4 20	—	+16.3%
Q4 23	—	+60.2%
Q1 24	—	+57.3%
Q3 24	—	+56.7%
Q4 24	—	+4.5%
Q1 25	—	-20.9%
Q2 25	—	-34.6%
Q3 25	—	+39.8%
Q4 25	—	-64.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 19	$219.9K	—
Q2 19	$190.1K	—
Q3 19	$183.0K	—
Q4 19	$481.3K	—
Q1 20	$287.1K	—
Q2 20	$190.5K	—
Q3 20	$146.9K	—
Q4 20	$1M	—
Q4 23	$554.7K	—
Q1 24	$420.9K	—
Q3 24	$325.2K	—
Q4 24	$874.0K	—
Q1 25	$882.8K	—
Q2 25	$382.2K	—
Q3 25	$3M	—
Q4 25	-$3M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 19	$2M	—	$1.3K
Q2 19	$3M	—	$1.3K
Q3 19	$1M	—	$1.3K
Q4 19	$2M	—	$3.0K
Q1 20	$2M	—	$2.2K
Q2 20	$2M	—	$2.2K
Q3 20	$3M	—	$1.8K
Q4 20	$3M	—	$2.9K
Q4 23	$3M	$3M	—
Q1 24	$4M	$2M	—
Q3 24	$5M	$2M	—
Q4 24	$3M	$3M	—
Q1 25	$3M	$2M	—
Q2 25	$2M	$2M	—
Q3 25	$5M	$5M	—
Q4 25	—	$4M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$29M	$0	$29M
Q2 22	$25M	$0	$25M
Q3 22	$24M	$0	$24M
Q4 22	$9M	$15M	$23M
Q1 23	$12M	$10M	$22M
Q2 23	$13M	$5M	$18M
Q3 23	$29M	$0	$29M
Q4 23	$26M	$0	$26M
Q1 24	$22M	$0	$22M
Q2 24	$18M	$0	$18M
Q3 24	$14M	$0	$14M
Q4 24	$12M	$0	$12M
Q1 25	$11M	$0	$11M
Q2 25	$11M	$0	$11M
Q3 25	$9M	$0	$9M
Q4 25	$5M	$0	$5M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 19	18M	0.0%	+23.1%
Q2 19	20M	+9.5%	+31.0%
Q3 19	23M	+12.2%	+36.9%
Q4 19	36M	+58.4%	+94.6%
Q1 20	37M	+3.8%	+102.1%
Q2 20	40M	+6.4%	+96.2%
Q3 20	42M	+5.3%	+84.3%
Q4 20	42M	0.0%	+16.3%
Q4 23	74M	+76.7%	+98.0%
Q1 24	75M	+2.1%	+90.0%
Q3 24	77M	+2.4%	+84.6%
Q4 24	76M	-1.2%	+82.4%
Q1 25	85M	+11.2%	+14.8%
Q2 25	91M	+7.5%	+20.9%
Q3 25	101M	+11.3%	+31.5%
Q4 25	96M	-5.4%	+26.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 19	$0	2
Q2 19	$0	2
Q3 19	$0	2
Q4 19	$0	2
Q1 20	$0	2
Q2 20	$0	2
Q3 20	$0	2
Q4 20	$0	2
Q4 23	$0	2
Q1 24	$0	2
Q3 24	$0	2
Q4 24	$0	2
Q1 25	$0	2
Q2 25	$0	2
Q3 25	$0	2
Q4 25	$0	29

Revenue / Employee